Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis

4 Followers

Caplin Point Laboratories Limited

(NSE:CAPLIPOINT)

Select Model

Rating:82Outperform

Price Target:INR 2,740.00▲(14.81% Upside)

Action:reiterated

Date:10/01/26

Caplin Point Laboratories achieves a strong overall score, driven predominantly by its exceptional fundamental health, zero-debt balance sheet, and impressive growth trajectory. While the stock's medium-to-long-term technical momentum remains favorable, the slightly premium P/E ratio and negligible dividend yield limit its valuation attractiveness. Investors should monitor the recent dip in gross margins, but the overarching financial stability makes it a highly compelling entity.

Positive Factors

Consistent Revenue GrowthRevenue growth has been consistent across the reported period, ranging from roughly 7% to 23% annually. That pattern indicates durable demand and execution rather than dependence on a single reporting period, supporting continued scale, product expansion, and operating leverage over the next several quarters.

Negative Factors

Uneven Free Cash Flow ConversionAlthough operating and free cash flow are positive, conversion has been uneven and has periodically lagged net income. Working-capital or investment swings can therefore make internally generated funding less predictable, potentially reducing flexibility for expansion or shareholder returns in weaker periods.

Caplin Point Laboratories Limited (CAPLIPOINT) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 181.57B
Dividend Yield: 0.34%
Average Volume (3M): 13.22K
Price to Earnings (P/E): 26.4
Beta (1Y): 1.12
Revenue Growth: 16.84%
EPS Growth: 17.02%
Country: India
Employees: 3,406
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited Business Overview & Revenue Model

Company Description

Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive produc...

How the Company Makes Money

Caplin Point primarily makes money by selling pharmaceutical products (mainly generic finished-dosage formulations) in domestic and international markets, with a significant portion of revenue historically coming from exports. Its key revenue streams...

Caplin Point Laboratories Limited Financial Statement Overview

Summary

Caplin Point Laboratories boasts an outstanding financial profile with revenues doubling over recent years and elite net profit margins nearing 29%. The balance sheet is a fortress with near-zero debt, ensuring immense stability, while operating cash flows remain robust, effectively self-funding operations despite slight moderation in free cash flow conversion.

Income Statement

92Very Positive

Balance Sheet

96Very Positive

Cash Flow

88Very Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	21.87B	21.87B	19.40B	16.96B	14.68B	12.71B
Gross Profit	11.15B	10.50B	11.38B	9.40B	7.89B	6.99B
EBITDA	8.53B	8.76B	6.53B	5.54B	4.43B	3.97B
Net Income	6.41B	6.41B	5.36B	4.57B	3.76B	3.00B
Balance Sheet
Total Assets	40.45B	40.45B	32.09B	26.98B	21.91B	17.36B
Cash, Cash Equivalents and Short-Term Investments	10.07B	10.07B	9.03B	7.88B	6.50B	5.13B
Total Debt	46.10M	46.10M	50.20M	19.70M	54.80M	21.30M
Total Liabilities	4.15B	4.15B	3.22B	3.51B	2.84B	2.26B
Stockholders Equity	35.86B	35.86B	28.50B	23.16B	18.80B	14.84B
Cash Flow
Free Cash Flow	1.60B	3.37B	2.41B	1.73B	779.00M	2.46B
Operating Cash Flow	2.54B	5.85B	4.32B	3.18B	2.72B	3.37B
Investing Cash Flow	-2.99B	-6.45B	-3.35B	-3.20B	-2.18B	-3.77B
Financing Cash Flow	-460.10M	-455.90M	-383.20M	-380.70M	-281.70M	-407.10M

Caplin Point Laboratories Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price2386.50

Price Trends

50DMA2547.59Negative

100DMA2550.68Negative

200DMA2184.97Positive

Market Momentum

MACD-20.46Negative

RSI46.58Neutral

STOCH41.93Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 2386.50 is above the 20-day moving average (MA) of 2348.13, below the 50-day MA of 2547.59, and above the 200-day MA of 2184.97, indicating a neutral trend. The MACD of -20.46 indicates Negative momentum. The RSI at 46.58 is Neutral, neither overbought nor oversold. The STOCH value of 41.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.

Caplin Point Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:CAPLIPOINT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:CAPLIPOINT	82Outperform	INR 181.55B	26.35	―	0.34%	16.84%	17.02%
IN:AKUMS	73Outperform	INR 118.12B	31.19	―	0.40%	17.50%	14.74%
IN:GRANULES	72Outperform	INR 208.36B	28.14	―	0.21%	21.75%	36.70%
IN:STAR	65Neutral	INR 92.92B	15.16	―	0.49%	11.28%	55.18%
IN:PPLPHARMA	56Neutral	INR 326.45B	-154.99	―	0.06%	9.43%	-767.49%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:JUBLPHARMA	49Neutral	INR 156.44B	43.35	―	0.52%	16.27%	-23.50%

* General Sector Average

Performance Comparison

IN:CAPLIPOINT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:CAPLIPOINT	Caplin Point Laboratories Limited	2386.50	448.68	23.15%
IN:AKUMS	Akums Drugs and Pharmaceuticals Limited	740.55	302.32	68.99%
IN:GRANULES	Granules India Limited	814.05	253.77	45.29%
IN:JUBLPHARMA	Jubilant Pharmova Limited	965.10	-187.68	-16.28%
IN:PPLPHARMA	Piramal Pharma Limited	244.65	49.10	25.11%
IN:STAR	Strides Pharma Science Ltd	1014.40	70.62	7.48%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026

Caplin Point Laboratories Limited AI Stock Analysis